0001209191-16-152233.txt : 20161128 0001209191-16-152233.hdr.sgml : 20161128 20161128194014 ACCESSION NUMBER: 0001209191-16-152233 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161123 FILED AS OF DATE: 20161128 DATE AS OF CHANGE: 20161128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS INC CENTRAL INDEX KEY: 0001175505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260038620 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-365-5600 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sarena Francis Willard CENTRAL INDEX KEY: 0001423786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36070 FILM NUMBER: 162021038 MAIL ADDRESS: STREET 1: C/O FIVE PRIME THERAPEUTICS, INC. STREET 2: 2 CORPORATE DRIVE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-11-23 0 0001175505 FIVE PRIME THERAPEUTICS INC FPRX 0001423786 Sarena Francis Willard TWO CORPORATE DRIVE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Strategy Officer Common Stock 2016-11-23 4 M 0 13465 6.89 A 94731 D Common Stock 2016-11-23 4 S 0 13465 60.23 D 81266 D Common Stock 2016-11-25 4 M 0 10925 6.89 A 92191 D Common Stock 2016-11-25 4 M 0 10264 5.54 A 102455 D Common Stock 2016-11-25 4 S 0 21189 60.48 D 81266 D Employee Stock Option (right to buy) 6.89 2016-11-23 4 M 0 13465 0.00 D 2021-01-27 Common Stock 13465 10925 D Employee Stock Option (right to buy) 6.89 2016-11-25 4 M 0 10925 0.00 D 2021-01-27 Common Stock 10925 0 D Employee Stock Option (right to buy) 5.54 2016-11-25 4 M 0 10264 0.00 D 2022-07-15 Common Stock 10264 14488 D The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on October 27, 2015. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.40, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.98, inclusive. This option is fully vested and immediately exercisable. /s/ Francis Sarena, Attorney-in-Fact 2016-11-28